UA102997U - METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES - Google Patents

METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES

Info

Publication number
UA102997U
UA102997U UAU201505760U UAU201505760U UA102997U UA 102997 U UA102997 U UA 102997U UA U201505760 U UAU201505760 U UA U201505760U UA U201505760 U UAU201505760 U UA U201505760U UA 102997 U UA102997 U UA 102997U
Authority
UA
Ukraine
Prior art keywords
diabetes
type
types
experimental reproduction
days
Prior art date
Application number
UAU201505760U
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAU201505760U priority Critical patent/UA102997U/en
Publication of UA102997U publication Critical patent/UA102997U/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Спосіб експериментального відтворення основних патогенетичних ланок цукрового діабету 2 типу у щурів шляхом впливу комбінованої дієти та хімічного агента. Статевозрілих самців-щурів лінії Вістар утримують на високожировому раціоні харчування у сполученні з надмірним споживанням вуглеводів протягом 90 діб, починаючи з 91 доби, протягом 5 діб роблять внутрішньочеревні ін'єкції розчину дексаметазону у дозі 1,0 мг/кг маси тіла один раз на добу.Method for experimental reproduction of major pathogenetic units of type 2 diabetes in rats by exposure to combined diet and chemical agent. Mature male Wistar rats are maintained on a high-fat diet in combination with excessive carbohydrate intake for 90 days, starting at 91 days, for intrauterine injections of a solution of dexamethasone at a dose of 1.0 mg / kg body weight once a day .

UAU201505760U 2015-06-11 2015-06-11 METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES UA102997U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201505760U UA102997U (en) 2015-06-11 2015-06-11 METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201505760U UA102997U (en) 2015-06-11 2015-06-11 METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES

Publications (1)

Publication Number Publication Date
UA102997U true UA102997U (en) 2015-11-25

Family

ID=55171375

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201505760U UA102997U (en) 2015-06-11 2015-06-11 METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES

Country Status (1)

Country Link
UA (1) UA102997U (en)

Similar Documents

Publication Publication Date Title
PE20151947A1 (en) REDUCTION OF THE PRO-INFLAMMATORY RESPONSE
BR112014002788A2 (en) polymer-based occlusion devices, systems and methods
PE20190338A1 (en) METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL
CL2015002677A1 (en) Compositions comprising selenium and their use for the treatment and prevention of diseases or conditions associated with mitochondrial dysfunction.
EA201400202A1 (en) APPLICATION OF ESTHETROL AS AN EMERGENCY CONTRACTIVE
EA201690964A1 (en) COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR PHENOMENA
PH12018501072A1 (en) Modified release orally administered amino acid formulations
MX2016012799A (en) Methods for treating hcv.
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
BR112017014361A2 (en) methods for perfecting cell therapy
PE20191044A1 (en) PHARMACEUTICAL COMPOSITION
MX2020004063A (en) Systems and methods to produce b cells genetically modified to express selected antibodies.
RU2010118082A (en) METHOD FOR TREATING RED FLAT
PH12015502100A1 (en) Reducing the risk of autoimmune disease
UA102997U (en) METHOD OF EXPERIMENTAL REPRODUCTION OF THE MAIN PATHOGENETIC TYPES OF TYPE 2 DIABETES
PH12015502657A1 (en) Interactions of betanodaviruses in infection
MX2019004894A (en) Mucosal active agent delivery.
MD4317B1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure
UA117879U (en) METHOD OF HORMONAL STIMULATION OF DUMES OF DANUBE SALMON
UA97018U (en) METHOD OF TREATMENT OF UROGENITAL INFECTIONS IN WOMEN WITH DISORDERS OF THE REPRODUCTIVE FUNCTION
CO2018001531A2 (en) Lisobactin for use in the treatment of bovine mastitis
RU2010111324A (en) METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH ADMA-SIMILAR PATHOLOGY MODEL IN PREGNANT ANIMALS
RU2013100472A (en) METHOD FOR MODELING ACQUIRED TOXIC HEMOLYTIC ANEMIA ON THE BACKGROUND OF ACUTE STRESS
RU2011115020A (en) METHOD FOR TREATING PATIENTS WITH ERYTHEMATOSIS-PAPULOUS FORM OF ROSATSEA
UA112676U (en) METHOD OF CORRECTION OF ANTI-OXIDANT SYSTEM OF ANIMAL INDICATORS UNDER TETRACHLOROMETHAN poisoning